- PROFESSOR Medicine, Infectious Diseases
American Board of Internal Medicine
New York Presbyterian Medical Center / Columbia
* Albert Einstein College of Medicine *
- David C. Perlman, MD is Professor of Medicine and Associate Chief, Infectious Diseases at Mount Sinai Beth Israel. He is also Investigator in the Baron Edmund De Rothschild Chemical Dependency Institute at Mount Sinai Beth Israel, and a member of the Institute of Advanced Medicine.
He has over 20 years’ experience in HIV, HCV and related in substance using population and remains active as a clinician in these areas. He has served as principal investigator on multi-center trials within NIAID’s AIDS Clinical Trials group, and on R01 grants from NIDA. He has served on NIH study sections, CDC consensus panels, committees within the ACTG and the NYS DOH AIDS Institute, and the Planning Committee of the NYCDOMH New York Hepatitis C Research Consortium. He is the Director, Infectious Diseases Core, in the NIDA-funded multi-institutional P30 Center for Drug Use and HIV Research (CDUHR) where his role is to facilitate multi-disciplinary interactions and research among biomedical and socio-behavioral scientists.
He is an active clinician, doing inpatient consultative infectious diseases and a full range of office infectious diseases.
The Leo M. Davidoff Society - for excellence in teaching
Fellow, Infectious Disease Society of America
College on Problems of Drug Dependence
2005 - 2006
President, Infectious Diseases Society of New York
2000 - 2003
TB Committee, Infectious Disease Society of
His earlier work focused on studies of the epidemiology of tuberculosis among drug users, and on health care delivery models and behavioral and structural interventions to facilitate adherence to the TB care continuum. Recent work has focused on the delivery of other health care services (HIV, STI, HCV, HBV, others) to drug users in and out of drug abuse treatment, a qualitative and quantitative study of barriers and facilitators of HIV and HCV testing and care among ethnic minority drug users, and a “seek, test, treat and retain” intervention for high risk heterosexuals. A prominent line of inquiry has been improving adherence to multi-step heath care interventions and care continua in a variety of settings, including extensive work with drug using populations in and out of drug abuse treatment settings. His current work focuses on the HCV care continuum. He was PI of the NIDA funded “Bridges” project, an RCT of a combined case management-motivational interviewing intervention to promote adherence to off-site referral for HCV care from methadone maintenance treatment (published in AJPH and selected for the AHRQ New Innovations Exchange). He is actively involved in a number of ongoing projects.
Carey J, Perlman DC, Friedmann P, Kaplan WM, Nugent A, Deutscher M, Masson CL, Des Jarlais DC. Knowledge of hepatitis among active drug injectors at a syringe exchange program. Journal of substance abuse treatment 2005 Jul; 29(1).
Perlman DC, Leung CC, Yew WW. Treatment of tuberculosis in HIV-infected patients: we need to know more. American journal of respiratory and critical care medicine 2007 Jun; 175(11).
Perlman DC, Leung CC, Yew WW. Diagnosing tuberculosis in patients with HIV: do we know enough?. American journal of respiratory and critical care medicine 2009 Nov; 180(9).
Des Jarlais DC, Arasteh K, McKnight C, Perlman D, Hagan H, Semaan S, Friedman SR. Gender and age patterns in HSV-2 and HIV infection among non-injecting drug users in New York City. Sexually transmitted diseases 2010 Oct; 37(10).
Ruhe JJ, Kreiswirth B, Perlman DC, Mildvan D, Koll B. Impact of results of methicillin-resistant Staphylococcus aureus surveillance culture of nasal specimens on subsequent antibiotic prescribing patterns. Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2010 Aug; 31(8).
Des Jarlais DC, Arasteh K, McKnight C, Hagan H, Perlman DC, Torian LV, Beatice S, Semaan S, Friedman SR. HIV infection during limited versus combined HIV prevention programs for IDUs in New York City: the importance of transmission behaviors. Drug and alcohol dependence 2010 Jun; 109(1-3).
Deren S, Hagan H, Friedman S, Des Jarlais DC, Perlman D, Gwadz M, Cleland C, Osborne A, Lunievicz J. Current and emerging research needs in studying the NYC HIV-drug use epidemic. Substance use & misuse 2011; 46(2-3).
Hagan H, Perlman DC, Des Jarlais DC. Sexual risk and HIV infection among drug users in New York City: a pilot study. Substance use & misuse 2011; 46(2-3).
Ruhe JJ, de Guzman L, Moss M, Riley W, Mildvan D, Perlman DC, Koll B. Methicillin-susceptible Staphylococcus aureus nasal colonization and the risk of subsequent methicillin-resistant Staphylococcus aureus infections among hospitalized patients. Diagnostic microbiology and infectious disease 2011 Oct; 71(2).
Des Jarlais DC, Hagan H, Arasteh K, McKnight C, Semaan S, Perlman DC. Can intranasal drug use reduce HCV infection among injecting drug users?. Drug and alcohol dependence 2011 Dec; 119(3).
De Guzman L, Perlman DC, Hubbard CE. Septic arthritis and osteomyelitis due to the chromoblastomycosis agent Fonsecaea pedrosoi. American journal of orthopedics (Belle Mead, N.J.) 2012 Jul; 41(7).
Talal AH, Dimova RB, Seewald R, Peterson RH, Zeremski M, Perlman DC, Des Jarlais DC. Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment. Journal of substance abuse treatment 2013 Jan; 44(1).
Mizusawa M, Perlman DC, Lucido D, Salomon N. Rapid loss of vaccine-acquired hepatitis B surface antibody after three doses of hepatitis B vaccination in HIV-infected persons. International journal of STD & AIDS 2014 Mar; 25(3).
Des Jarlais DC, McKnight C, Arasteh K, Feelemyer J, Perlman DC, Hagan H, Dauria EF, Cooper HL. A perfect storm: crack cocaine, HSV-2, and HIV among non-injecting drug users in New York City. Substance use & misuse 2014 Jun; 49(7).
Goldstein RC, Husk G, Jodlowski T, Mildvan D, Perlman DC, Ruhe JJ. Fluoroquinolone- and ceftriaxone-based therapy of community-acquired pneumonia in hospitalized patients: the risk of subsequent isolation of multidrug-resistant organisms. American journal of infection control 2014 May; 42(5).
Perlman DC, Gelpí-Acosta C, Friedman SR, Jordan AE, Hagan H. Perceptions of genetic testing and genomic medicine among drug users. The International journal on drug policy 2014 Jun;.
Des Jarlais DC, Fisher DG, Newman JC, Trubatch BN, Yancovitz M, Paone D, Perlman D. Providing hepatitis B vaccination to injection drug users: referral to health clinics vs on-site vaccination at a syringe exchange program. American journal of public health 2001 Nov; 91(11).
Sorensen JL, Masson CL, Perlman DC. HIV/hepatitis prevention in drug abuse treatment programs: guidance from research. Science & practice perspectives / a publication of the National Institute on Drug Abuse, National Institutes of Health 2002 Jul; 1(1).
Masson CL, Sorensen JL, Perlman DC, Shopshire MS, Delucchi KL, Chen T, Sporer K, Des Jarlais D, Hall SM. Hospital- versus community-based syringe exchange: a randomized controlled trial. AIDS education and prevention : official publication of the International Society for AIDS Education 2007 Apr; 19(2).
Coffin LS, Newberry A, Hagan H, Cleland CM, Des Jarlais DC, Perlman DC. Syphilis in drug users in low and middle income countries. The International journal on drug policy 2010 Jan; 21(1).
Masson CL, Sorensen JL, Grossman N, Sporer KA, Des Jarlais DC, Perlman DC. Organizational issues in the implementation of a hospital-based syringe exchange program. Substance use & misuse 2010 May; 45(6).
Des Jarlais DC, Arasteh K, McKnight C, Hagan H, Perlman DC, Semaan S. Associations between herpes simplex virus type 2 and HCV With HIV among injecting drug users in New York City: the current importance of sexual transmission of HIV. American journal of public health 2011 Jul; 101(7).
Jordan AE, Masson CL, Mateu-Gelabert P, McKnight C, Pepper N, Bouche K, Guzman L, Kletter E, Seewald RM, Des-Jarlais DC, Sorensen JL, Perlman DC. Perceptions of drug users regarding hepatitis C screening and care: a qualitative study. Harm reduction journal 2013; 10.
Masson CL, Delucchi KL, McKnight C, Hettema J, Khalili M, Min A, Jordan AE, Pepper N, Hall J, Hengl NS, Young C, Shopshire MS, Manuel JK, Coffin L, Hammer H, Shapiro B, Seewald RM, Bodenheimer HC, Sorensen JL, Des Jarlais DC, Perlman DC. A randomized trial of a hepatitis care coordination model in methadone maintenance treatment. American journal of public health 2013 Oct; 103(10).
Dhingra L, Masson C, Perlman DC, Seewald RM, Katz J, McKnight C, Homel P, Wald E, Jordan AE, Young C, Portenoy RK. Epidemiology of pain among outpatients in methadone maintenance treatment programs. Drug and alcohol dependence 2013 Feb; 128(1-2).
Friedman SR, Sandoval M, Mateu-Gelabert P, Rossi D, Gwadz M, Dombrowski K, Smyrnov P, Vasylyeva T, Pouget ER, Perlman D. Theory, measurement and hard times: some issues for HIV/AIDS research. AIDS and behavior 2013 Jul; 17(6).
Seewald R, Bruce RD, Elam R, Tio R, Lorenz S, Friedmann P, Rabin D, Garger YB, Bonilla V, Perlman DC. Effectiveness and feasibility study of routine HIV rapid testing in an urban methadone maintenance treatment program. The American journal of drug and alcohol abuse 2013 Jul; 39(4).
Des Jarlais DC, Arasteh K, McKnight C, Perlman DC, Cooper HL, Hagan H. HSV-2 Infection as a Cause of Female/Male and Racial/Ethnic Disparities in HIV Infection. PloS one 2013; 8(6).
Nigo M, Cevallos CS, Woods K, Flores VM, Francis G, Perlman DC, Revuelta M, Mildvan D, Waldron M, Gomez T, Koshy S, Jodlowski T, Riley W, Ruhe JJ. Nested case-control study of the emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae. Antimicrobial agents and chemotherapy 2013 Nov; 57(11).
Des Jarlais DC, McKnight C, Arasteh K, Feelemyer J, Perlman D, Hagan H, Cooper HL. Use of the . Journal of urban health : bulletin of the New York Academy of Medicine 2014 Jun; 91(3).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Perlman did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.
Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.
Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website.